The prognostic importance of cystatin C in severe systolic dysfunction without chronic kidney disease To the Editor: Cystatin C has been identified as a novel biomarker that is more sensitive in detecting early kidney dysfunction. We aimed to investigate the prognostic importance of cystatin C in stable heart failure patients who had an ejection fraction (EF) of <35% and a glomerular filtration rate (GFR) of >60 mL/min/ 1.73 m 2 . Seventyfive stable heart failure patients (50 males and 25 females with a mean age (SD) of 67.6 (10.6) were included in this study. All patients were evaluated using Doppler echocardiography, and biochemical variables including measurement of cystatin C were measured at baseline. Patients were prospectively followed-up for 13(1) months. The endpoints were all-cause mortality For mortality rate, the same analyses revealed an independent risk with cystatin C, which did not reach significance (OR: 37.1, 95% CI, 0.94-1464, P=.054). According to ROC analysis, cystatin C levels >1.55 ng/mL could predict mortality with 82% sensitivity and 73% specificity. Furthermore, cystatin C levels >1.45 ng/mL could predict MACE rate with 76% sensitivity and 83% specificity. Kaplan-Meier analysis showed that patients who had serum cystatin C levels of >1.5 ng/mL had a significantly higher total death rate compared with lower levels (P<.001).
Cystatin C is a small serine protease inhibitor that is secreted from almost all active cells in the body. It has been identified as a novel biomarker that is more sensitive in detecting early kidney dysfunction compared with creatinine and creatinine-based estimated GFR. 1 Previous studies dealing with the prognostic value of cystain C in heart failure were conducted on patients with EF>40%.
1,2 Our results showed further insight about the prognostic value of cystatin C in stable heart failure patients who had lower ejection fraction (<35%). The results of the Cardiovascular Health Study showed that elevated cystatin C concentrations were associated with incrementally increasing mortality risk, particularly over 1.0 ng/mL. 3 The results of the study confirm the same result since none of the patients in our study group having a baseline cystatin C level of < 1 ng/mL died during follow-up.
